A new high-dose regimen of Spinraza (nusinersen) was recently approved in the U.S. as a treatment for spinal muscular atrophy (SMA), with clinical trial data showing a safety profile broadly consistent with the original 12 mg regimen, first approved a decade ago, and suggesting the potential for greater motor benefits. Richard Finkel, MD, director of […] The post New high-dose Spinraza regimen may offer added benefits in SMA appeared first on SMA News Today .

Source: https://smanewstoday.com/news/new-high-dose-spinraza-offers-another-option-sma-treatment/ (Fri, 01 May 2026)

Ingested by the SMA platform's daily smanewstoday.com RSS pipeline. Cross-linked to our knowledge graph via the news auto-scoring cron.